The burden of lung cancer in Latin-America and challenges in the access to genomic profiling, immunotherapy and targeted treatments

Vista sencilla de ítem
dc.contributor.authorRaez, Luis E.
dc.contributor.authorCardona-Mendoza, Andrés Felipe
dc.contributor.authorSantos, Edgardo S.
dc.contributor.authorCatoe, Heath
dc.contributor.authorRolfo, Christian
dc.contributor.authorLopes, Gilberto
dc.contributor.authorBarrios, Carlos
dc.contributor.authorMas, Luis A.
dc.contributor.authorVallejos, Carlos
dc.contributor.authorZatarain-Barrón, Zyanya Lucia
dc.contributor.authorCaglevic, Christian
dc.contributor.authorArrieta, Oscar
dc.contributor.orcidCardona-Mendoza, Andrés Felipe [0000-0002-6697-5471]
dc.date.accessioned2020-07-31T13:52:43Z
dc.date.available2020-07-31T13:52:43Z
dc.date.issued2018
dc.description.abstractenglishLung cancer is a public health problem worldwide and Latin America (LATAM) cannot escape this reality. This malignant disease has not only a high prevalence in the region, but is also the main cause of cancer related deaths, and in other emerging countries, the incidence rates are still on the rise. Interestingly in most LATAM countries, lung cancer mortality has been decreasing in men but not in women, reflecting smoking patterns in countries such as Chile, Bolivia, and Brazil. Despite the fact that these issues are well known to government agencies, physicians and patients in the region, current efforts still fall behind those needed in order to face this problem of epidemic proportions. Tobacco control and smoking cessation are the most important interventions against lung cancer, but even with their optimal implementation (which is far from reality at this time) the number of cases in the foreseeable future would still be significant. Beyond tobacco control, advances in our understanding of the molecular component of lung cancer have resulted in new targeted therapies and immune check point inhibitors, which have improved clinical outcomes but at a considerably higher financial cost. LATAM has not widely and speedily adopted these strategies, including new technology and approved novel drugs, due to a number of facts, and therefore only a dismal proportion of LATAḾs patient population have benefited from these new advances. A keen focus on a heterogeneous education system for caregivers in lung cancer treatment would likely help standardize care and improve future potential gains from domestic research. In this review we discuss the challenges of treatment implementation, focusing on new technologies.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.1016/j.lungcan.2018.02.014
dc.identifier.instnameinstname:Universidad El Bosquespa
dc.identifier.issn1872-8332
dc.identifier.reponamereponame:Repositorio Institucional Universidad El Bosquespa
dc.identifier.repourlhttps://repositorio.unbosque.edu.co
dc.identifier.urihttps://hdl.handle.net/20.500.12495/3631
dc.language.isoeng
dc.publisherElsevierspa
dc.publisher.journalLung cancerspa
dc.relation.ispartofseriesLung Cancer, 1872-8332, Vol. 119, 2018, p. 7-13spa
dc.relation.urihttps://www.lungcancerjournal.info/article/S0169-5002(18)30271-X/abstract
dc.rights.accessrightshttps://purl.org/coar/access_right/c_abf2
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.accessrightsAcceso abierto
dc.rights.creativecommons2018-05
dc.rights.localAcceso abiertospa
dc.subject.keywordsLung cancerspa
dc.subject.keywordsLatin Americaspa
dc.subject.keywordsImmunotherapyspa
dc.subject.keywordsTargeted therapyspa
dc.subject.keywordsHealthcare accessspa
dc.titleThe burden of lung cancer in Latin-America and challenges in the access to genomic profiling, immunotherapy and targeted treatmentsspa
dc.title.translatedThe burden of lung cancer in Latin-America and challenges in the access to genomic profiling, immunotherapy and targeted treatmentsspa
dc.type.coarhttps://purl.org/coar/resource_type/c_6501
dc.type.driverinfo:eu-repo/semantics/article
dc.type.hasversioninfo:eu-repo/semantics/publishedVersion
dc.type.localArtículo de revista

Archivos

Bloque original
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
Raez, Luis E..pdf
Tamaño:
216.57 KB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos